There are more than 500 distinct protein kinases in the cell that form a complex interaction network and by reversible protein phosphorylation regulate intracellular signal transduction. Dysfunction of kinase activity can cause many human diseases and since protein kinases are critical initiators, mediators and amplifiers of multiple signaling pathways associated with malignant transformation and aggressiveness of the disease, they remain a major focus of research initiatives identifying novel targeted therapies. Selvita started its first kinase discovery programs in 2008. Set of research tools developed within the platform enables fast target validation and the rapid and effective development of kinase inhibitors.
In September 2013 Selvita entered into strategic partnership with the US based biotech company – H3 Biomedicine. The aim of the joint project is development of innovative anticancer therapies with the use of small molecule inhibitors acting on two novel kinase targets associated with oncogenic signaling pathways in cancer.